Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus

Author(s): Predrag Dugalic*, Srdjan Djuranovic, Aleksandra Pavlovic-Markovic, Vladimir Dugalic, Ratko Tomasevic, Zoran Gluvic, Milan Obradovic, Vladan Bajic, Esma R. Isenovic*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 20 , Issue 11 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Gastroesophageal Reflux Disease (GERD) is characterized by acid and bile reflux in the distal oesophagus, and this may cause the development of reflux esophagitis and Barrett’s oesophagus (BE). The natural histological course of untreated BE is non-dysplastic or benign BE (ND), then lowgrade (LGD) and High-Grade Dysplastic (HGD) BE, with the expected increase in malignancy transfer to oesophagal adenocarcinoma (EAC). The gold standard for BE diagnostics involves high-resolution white-light endoscopy, followed by uniform endoscopy findings description (Prague classification) with biopsy performance according to Seattle protocol. The medical treatment of GERD and BE includes the use of proton pump inhibitors (PPIs) regarding symptoms control. It is noteworthy that long-term use of PPIs increases gastrin level, which can contribute to transfer from BE to EAC, as a result of its effects on the proliferation of BE epithelium. Endoscopy treatment includes a wide range of resection and ablative techniques, such as radio-frequency ablation (RFA), often concomitantly used in everyday endoscopy practice (multimodal therapy). RFA promotes mucosal necrosis of treated oesophagal region via high-frequency energy. Laparoscopic surgery, partial or total fundoplication, is reserved for PPIs and endoscopy indolent patients or in those with progressive disease. This review aims to explain distinct effects of PPIs and RFA modalities, illuminate certain aspects of molecular mechanisms involved, as well as the effects of their concomitant use regarding the treatment of BE and prevention of its transfer to EAC.

Keywords: GERD, Barrett's oesophagus, proton pump inhibitors, radio-frequency ablation, action of PPIs, oesophagus.

[1]
Barrett, N.R. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br. J. Surg., 1950, 38(150), 175-182.
[http://dx.doi.org/10.1002/bjs.18003815005] [PMID: 14791960]
[2]
El-Serag, H.B.; Sweet, S.; Winchester, C.C.; Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2014, 63(6), 871-880.
[http://dx.doi.org/10.1136/gutjnl-2012-304269] [PMID: 23853213]
[3]
Taylor, J.B.; Rubenstein, J.H. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus. Am. J. Gastroenterol., 2010, 105(8), 1729-1730.
[4]
Zagari, R.M.; Fuccio, L.; Wallander, M.A.; Johansson, S.; Fiocca, R.; Casanova, S.; Farahmand, B.Y.; Winchester, C.C.; Roda, E.; Bazzoli, F. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut, 2008, 57(10), 1354-1359.
[http://dx.doi.org/10.1136/gut.2007.145177] [PMID: 18424568]
[5]
Ronkainen, J.; Aro, P.; Storskrubb, T.; Johansson, S.E.; Lind, T.; Bolling-Sternevald, E.; Vieth, M.; Stolte, M.; Talley, N.J.; Agréus, L. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology, 2005, 129(6), 1825-1831.
[http://dx.doi.org/10.1053/j.gastro.2005.08.053] [PMID: 16344051]
[6]
Whiteman, D.C.; Kendall, B.J. Barrett’s oesophagus: epidemiology, diagnosis and clinical management. Med. J. Aust., 2016, 205(7), 317-324.
[http://dx.doi.org/10.5694/mja16.00796] [PMID: 27681974]
[7]
Connor, M.J.; Weston, A.P.; Mayo, M.S.; Sharma, P. The prevalence of Barrett’s esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population. Dig. Dis. Sci., 2004, 49(6), 920-924.
[http://dx.doi.org/10.1023/B:DDAS.0000034549.55326.67] [PMID: 15309878]
[8]
Sharma, P.; Dent, J.; Armstrong, D.; Bergman, J.J.; Gossner, L.; Hoshihara, Y.; Jankowski, J.A.; Junghard, O.; Lundell, L.; Tytgat, G.N.; Vieth, M. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology, 2006, 131(5), 1392-1399.
[http://dx.doi.org/10.1053/j.gastro.2006.08.032] [PMID: 17101315]
[9]
Spechler, S.J.; Sharma, P.; Souza, R.F.; Inadomi, J.M.; Shaheen, N.J. American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology, 2011, 140(3), e18-e52.
[http://dx.doi.org/10.1053/j.gastro.2011.01.031] [PMID: 21376939]
[10]
Martinucci, I.; de Bortoli, N.; Russo, S.; Bertani, L.; Furnari, M.; Mokrowiecka, A.; Malecka-Panas, E.; Savarino, V.; Savarino, E.; Marchi, S. Barrett’s esophagus in 2016: From pathophysiology to treatment. World J. Gastrointest. Pharmacol. Ther., 2016, 7(2), 190-206.
[http://dx.doi.org/10.4292/wjgpt.v7.i2.190] [PMID: 27158534]
[11]
Shaheen, N.J.; Falk, G.W.; Iyer, P.G.; Gerson, L.B. American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am. J. Gastroenterol., 2016, 111(1), 30-50.
[http://dx.doi.org/10.1038/ajg.2015.322] [PMID: 26526079]
[12]
Brown, C.S.; Lapin, B.; Wang, C.; Goldstein, J.L.; Linn, J.G.; Denham, W.; Haggerty, S.P.; Talamonti, M.S.; Howington, J.A.; Carbray, J.; Ujiki, M.B. Reflux control is important in the management of Barrett’s Esophagus: results from a retrospective 1,830 patient cohort. Surg. Endosc., 2015, 29(12), 3528-3534.
[http://dx.doi.org/10.1007/s00464-015-4103-3] [PMID: 25676204]
[13]
Hillman, L.C.; Chiragakis, L.; Shadbolt, B.; Kaye, G.L.; Clarke, A.C. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med. J. Aust., 2004, 180(8), 387-391.
[PMID: 15089728]
[14]
Kastelein, F.; Spaander, M.C.; Steyerberg, E.W.; Biermann, K.; Valkhoff, V.E.; Kuipers, E.J.; Bruno, M.J. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin. Gastroenterol. Hepatol., 2013, 11(4), 382-388.
[http://dx.doi.org/10.1016/j.cgh.2012.11.014] [PMID: 23200977]
[15]
Corley, D.A.; Kerlikowske, K.; Verma, R.; Buffler, P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology, 2003, 124(1), 47-56.
[http://dx.doi.org/10.1053/gast.2003.50008] [PMID: 12512029]
[16]
Epithelial radiofrequency ablation for Barrett's oesophagus. Interventional procedures guidance [IPG344], National Institute for Health and Clinical Excellence. 2010.
[17]
Sappati Biyyani, R.S.; Chak, A. Barrett’s esophagus: review of diagnosis and treatment. Gastroenterol. Rep. (Oxf.), 2013, 1(1), 9-18.
[http://dx.doi.org/10.1093/gastro/got015] [PMID: 24759662]
[18]
Bennett, C.; Vakil, N.; Bergman, J.; Harrison, R.; Odze, R.; Vieth, M.; Sanders, S.; Gay, L.; Pech, O.; Longcroft-Wheaton, G.; Romero, Y.; Inadomi, J.; Tack, J.; Corley, D.A.; Manner, H.; Green, S.; Al Dulaimi, D.; Ali, H.; Allum, B.; Anderson, M.; Curtis, H.; Falk, G.; Fennerty, M.B.; Fullarton, G.; Krishnadath, K.; Meltzer, S.J.; Armstrong, D.; Ganz, R.; Cengia, G.; Going, J.J.; Goldblum, J.; Gordon, C.; Grabsch, H.; Haigh, C.; Hongo, M.; Johnston, D.; Forbes-Young, R.; Kay, E.; Kaye, P.; Lerut, T.; Lovat, L.B.; Lundell, L.; Mairs, P.; Shimoda, T.; Spechler, S.; Sontag, S.; Malfertheiner, P.; Murray, I.; Nanji, M.; Poller, D.; Ragunath, K.; Regula, J.; Cestari, R.; Shepherd, N.; Singh, R.; Stein, H.J.; Talley, N.J.; Galmiche, J.P.; Tham, T.C.; Watson, P.; Yerian, L.; Rugge, M.; Rice, T.W.; Hart, J.; Gittens, S.; Hewin, D.; Hochberger, J.; Kahrilas, P.; Preston, S.; Sampliner, R.; Sharma, P.; Stuart, R.; Wang, K.; Waxman, I.; Abley, C.; Loft, D.; Penman, I.; Shaheen, N.J.; Chak, A.; Davies, G.; Dunn, L.; Falck-Ytter, Y.; Decaestecker, J.; Bhandari, P.; Ell, C.; Griffin, S.M.; Attwood, S.; Barr, H.; Allen, J.; Ferguson, M.K.; Moayyedi, P.; Jankowski, J.A. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, 2012, 143(2), 336-346.
[http://dx.doi.org/10.1053/j.gastro.2012.04.032] [PMID: 22537613]
[19]
Falk, G.W. Updated Guidelines for Diagnosing and Managing Barrett Esophagus. Gastroenterol. Hepatol. (N. Y.), 2016, 12(7), 449-451.
[PMID: 27489529]
[20]
Galmiche, J.P.; Hatlebakk, J.; Attwood, S.; Ell, C.; Fiocca, R.; Eklund, S.; Långström, G.; Lind, T.; Lundell, L. LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA, 2011, 305(19), 1969-1977.
[http://dx.doi.org/10.1001/jama.2011.626] [PMID: 21586712]
[21]
Amadi, C.; Gatenby, P. Barrett’s oesophagus: Current controversies. World J. Gastroenterol., 2017, 23(28), 5051-5067.
[http://dx.doi.org/10.3748/wjg.v23.i28.5051] [PMID: 28811703]
[22]
Thrift, A.P.; Kramer, J.R.; Qureshi, Z.; Richardson, P.A.; El-Serag, H.B. Age at onset of GERD symptoms predicts risk of Barrett’s esophagus. Am. J. Gastroenterol., 2013, 108(6), 915-922.
[http://dx.doi.org/10.1038/ajg.2013.72] [PMID: 23567358]
[23]
Chak, A.; Lee, T.; Kinnard, M.F.; Brock, W.; Faulx, A.; Willis, J.; Cooper, G.S.; Sivak, M.V., Jr; Goddard, K.A. Familial aggregation of Barrett’s oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut, 2002, 51(3), 323-328.
[http://dx.doi.org/10.1136/gut.51.3.323] [PMID: 12171951]
[24]
van Blankenstein, M.; Looman, C.W.; Johnston, B.J.; Caygill, C.P. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am. J. Gastroenterol., 2005, 100(3), 568-576.
[http://dx.doi.org/10.1111/j.1572-0241.2005.40187.x] [PMID: 15743353]
[25]
Runge, T.M.; Abrams, J.A.; Shaheen, N.J. Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North Am., 2015, 44(2), 203-231.
[http://dx.doi.org/10.1016/j.gtc.2015.02.001] [PMID: 26021191]
[26]
Corley, D.A.; Kubo, A.; Levin, T.R.; Block, G.; Habel, L.; Rumore, G.; Quesenberry, C.; Buffler, P. Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994-2006. Gut, 2009, 58(2), 182-188.
[http://dx.doi.org/10.1136/gut.2008.163360] [PMID: 18978173]
[27]
Cook, M.B.; Wild, C.P.; Forman, D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am. J. Epidemiol., 2005, 162(11), 1050-1061.
[http://dx.doi.org/10.1093/aje/kwi325] [PMID: 16221805]
[28]
Andrici, J.; Cox, M.R.; Eslick, G.D. Cigarette smoking and the risk of Barrett’s esophagus: a systematic review and meta-analysis. J. Gastroenterol. Hepatol., 2013, 28(8), 1258-1273.
[http://dx.doi.org/10.1111/jgh.12230] [PMID: 23611750]
[29]
Cook, M.B.; Shaheen, N.J.; Anderson, L.A.; Giffen, C.; Chow, W.H.; Vaughan, T.L.; Whiteman, D.C.; Corley, D.A. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Gastroenterology, 2012, 142(4), 744-753.
[http://dx.doi.org/10.1053/j.gastro.2011.12.049] [PMID: 22245667]
[30]
Kendall, B.J.; Macdonald, G.A.; Hayward, N.K.; Prins, J.B.; O’Brien, S.; Whiteman, D.C. Study of Digestive Health. The risk of Barrett’s esophagus associated with abdominal obesity in males and females. Int. J. Cancer, 2013, 132(9), 2192-2199.
[http://dx.doi.org/10.1002/ijc.27887] [PMID: 23034724]
[31]
Thrift, A.P.; Shaheen, N.J.; Gammon, M.D.; Bernstein, L.; Reid, B.J.; Onstad, L.; Risch, H.A.; Liu, G.; Bird, N.C.; Wu, A.H.; Corley, D.A.; Romero, Y.; Chanock, S.J.; Chow, W.H.; Casson, A.G.; Levine, D.M.; Zhang, R.; Ek, W.E.; MacGregor, S.; Ye, W.; Hardie, L.J.; Vaughan, T.L.; Whiteman, D.C. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J. Natl. Cancer Inst., 2014, 106(11) dju252
[http://dx.doi.org/10.1093/jnci/dju252] [PMID: 25269698]
[32]
Leggett, C.L.; Nelsen, E.M.; Tian, J.; Schleck, C.B.; Zinsmeister, A.R.; Dunagan, K.T.; Locke, G.R., III; Wang, K.K.; Talley, N.J.; Iyer, P.G. Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study. Mayo Clin. Proc., 2013, 88(2), 157-165.
[http://dx.doi.org/10.1016/j.mayocp.2012.09.017] [PMID: 23374619]
[33]
Iyer, P.G.; Borah, B.J.; Heien, H.C.; Das, A.; Cooper, G.S.; Chak, A. Association of Barrett’s esophagus with type II Diabetes Mellitus: results from a large population-based case-control study. Clin. Gastroenterol. Hepatol., 2013, 11(9), 1108-1114.e5.
[http://dx.doi.org/10.1016/j.cgh.2013.03.024] [PMID: 23591277]
[34]
Leggett, C.L.; Gorospe, E.C.; Calvin, A.D.; Harmsen, W.S.; Zinsmeister, A.R.; Caples, S.; Somers, V.K.; Dunagan, K.; Lutzke, L.; Wang, K.K.; Iyer, P.G. Obstructive sleep apnea is a risk factor for Barrett’s esophagus. Clin. Gastroenterol. Hepatol., 2014, 12(4), 583-8.e1.
[http://dx.doi.org/10.1016/j.cgh.2013.08.043] [PMID: 24035775]
[35]
Greer, K.B.; Thompson, C.L.; Brenner, L.; Bednarchik, B.; Dawson, D.; Willis, J.; Grady, W.M.; Falk, G.W.; Cooper, G.S.; Li, L.; Chak, A. Association of insulin and insulin-like growth factors with Barrett’s oesophagus. Gut, 2012, 61(5), 665-672.
[http://dx.doi.org/10.1136/gutjnl-2011-300641] [PMID: 21930730]
[36]
Kendall, B.J.; Macdonald, G.A.; Hayward, N.K.; Prins, J.B.; Brown, I.; Walker, N.; Pandeya, N.; Green, A.C.; Webb, P.M.; Whiteman, D.C. Study of Digestive Health. Leptin and the risk of Barrett’s oesophagus. Gut, 2008, 57(4), 448-454.
[http://dx.doi.org/10.1136/gut.2007.131243] [PMID: 18178609]
[37]
Corley, D.A.; Kubo, A.; Levin, T.R.; Block, G.; Habel, L.; Zhao, W.; Leighton, P.; Rumore, G.; Quesenberry, C.; Buffler, P.; Parsonnet, J. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut, 2008, 57(6), 727-733.
[http://dx.doi.org/10.1136/gut.2007.132068] [PMID: 17895354]
[38]
Thrift, A.P.; Pandeya, N.; Smith, K.J.; Green, A.C.; Hayward, N.K.; Webb, P.M.; Whiteman, D.C. Helicobacter pylori infection and the risks of Barrett’s oesophagus: a population-based case-control study. Int. J. Cancer, 2012, 130(10), 2407-2416.
[http://dx.doi.org/10.1002/ijc.26242] [PMID: 21681741]
[39]
Francois, F.; Roper, J.; Goodman, A.J.; Pei, Z.; Ghumman, M.; Mourad, M.; de Perez, A.Z.; Perez-Perez, G.I.; Tseng, C.H.; Blaser, M.J. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut, 2008, 57(1), 16-24.
[http://dx.doi.org/10.1136/gut.2007.131672] [PMID: 17761783]
[40]
Nwokolo, C.U.; Freshwater, D.A.; O’Hare, P.; Randeva, H.S. Plasma ghrelin following cure of Helicobacter pylori. Gut, 2003, 52(5), 637-640.
[http://dx.doi.org/10.1136/gut.52.5.637] [PMID: 12692045]
[41]
Kuipers, E.J.; Spaander, M.C. Natural History of Barrett’s Esophagus. Dig. Dis. Sci., 2018, 63(8), 1997-2004.
[http://dx.doi.org/10.1007/s10620-018-5161-x] [PMID: 29905908]
[42]
Zou, D.; He, J.; Ma, X.; Chen, J.; Gong, Y.; Man, X.; Gao, L.; Wang, R.; Zhao, Y.; Yan, X.; Liu, W.; Wernersson, B.; Johansson, S.; Dent, J.; Sung, J.J.; Li, Z. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand. J. Gastroenterol., 2011, 46(2), 133-141.
[http://dx.doi.org/10.3109/00365521.2010.521888] [PMID: 20955088]
[43]
Shiota, S.; Singh, S.; Anshasi, A.; El-Serag, H.B. Prevalence of Barrett’s Esophagus in asian countries: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2015, 13(11), 1907-1918.
[http://dx.doi.org/10.1016/j.cgh.2015.07.050] [PMID: 26260107]
[44]
Fock, K.M.; Ang, T.L. Global epidemiology of Barrett’s esophagus. Expert Rev. Gastroenterol. Hepatol., 2011, 5(1), 123-130.
[http://dx.doi.org/10.1586/egh.10.82] [PMID: 21309677]
[45]
McDonald, S.A.; Lavery, D.; Wright, N.A.; Jansen, M. Barrett oesophagus: lessons on its origins from the lesion itself. Nat. Rev. Gastroenterol. Hepatol., 2015, 12(1), 50-60.
[http://dx.doi.org/10.1038/nrgastro.2014.181] [PMID: 25365976]
[46]
Wang, X.; Ouyang, H.; Yamamoto, Y.; Kumar, P.A.; Wei, T.S.; Dagher, R.; Vincent, M.; Lu, X.; Bellizzi, A.M.; Ho, K.Y.; Crum, C.P.; Xian, W.; McKeon, F. Residual embryonic cells as precursors of a Barrett’s-like metaplasia. Cell, 2011, 145(7), 1023-1035.
[http://dx.doi.org/10.1016/j.cell.2011.05.026] [PMID: 21703447]
[47]
Quante, M.; Bhagat, G.; Abrams, J.A.; Marache, F.; Good, P.; Lee, M.D.; Lee, Y.; Friedman, R.; Asfaha, S.; Dubeykovskaya, Z.; Mahmood, U.; Figueiredo, J.L.; Kitajewski, J.; Shawber, C.; Lightdale, C.J.; Rustgi, A.K.; Wang, T.C. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell, 2012, 21(1), 36-51.
[http://dx.doi.org/10.1016/j.ccr.2011.12.004] [PMID: 22264787]
[48]
Jiang, M.; Li, H.; Zhang, Y.; Yang, Y.; Lu, R.; Liu, K.; Lin, S.; Lan, X.; Wang, H.; Wu, H.; Zhu, J.; Zhou, Z.; Xu, J.; Lee, D.K.; Zhang, L.; Lee, Y.C.; Yuan, J.; Abrams, J.A.; Wang, T.C.; Sepulveda, A.R.; Wu, Q.; Chen, H.; Sun, X.; She, J.; Chen, X.; Que, J. Transitional basal cells at the squamous-columnar junction generate Barrett’s oesophagus. Nature, 2017, 550(7677), 529-533.
[http://dx.doi.org/10.1038/nature24269] [PMID: 29019984]
[49]
Inadomi, J.; Alastal, H.; Bonavina, L.; Gross, S.; Hunt, R.H.; Mashimo, H.; di Pietro, M.; Rhee, H.; Shah, M.; Tolone, S.; Wang, D.H.; Xie, S.H. Recent advances in Barrett’s esophagus. Ann. N. Y. Acad. Sci., 2018, 1434(1), 227-238.
[http://dx.doi.org/10.1111/nyas.13909] [PMID: 29974975]
[50]
Yamamoto, Y.; Wang, X.; Bertrand, D.; Kern, F.; Zhang, T.; Duleba, M.; Srivastava, S.; Khor, C.C.; Hu, Y.; Wilson, L.H.; Blaszyk, H.; Rolshud, D.; Teh, M.; Liu, J.; Howitt, B.E.; Vincent, M.; Crum, C.P.; Nagarajan, N.; Ho, K.Y.; McKeon, F.; Xian, W. Mutational spectrum of Barrett’s stem cells suggests paths to initiation of a precancerous lesion. Nat. Commun., 2016, 7, 10380.
[http://dx.doi.org/10.1038/ncomms10380] [PMID: 26783136]
[51]
Souza, R.F.; Huo, X.; Mittal, V.; Schuler, C.M.; Carmack, S.W.; Zhang, H.Y.; Zhang, X.; Yu, C.; Hormi-Carver, K.; Genta, R.M.; Spechler, S.J. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology, 2009, 137(5), 1776-1784.
[http://dx.doi.org/10.1053/j.gastro.2009.07.055] [PMID: 19660463]
[52]
Dunbar, K.B.; Agoston, A.T.; Odze, R.D.; Huo, X.; Pham, T.H.; Cipher, D.J.; Castell, D.O.; Genta, R.M.; Souza, R.F.; Spechler, S.J. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA, 2016, 315(19), 2104-2112.
[http://dx.doi.org/10.1001/jama.2016.5657] [PMID: 27187303]
[53]
Lavery, D.L.; Nicholson, A.M.; Poulsom, R. The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands, 2014, 63(12), 1854-1863.
[54]
Ross-Innes, C.S.; Becq, J.; Warren, A.; Cheetham, R.K.; Northen, H.; O’Donovan, M.; Malhotra, S.; di Pietro, M.; Ivakhno, S.; He, M.; Weaver, J.M.J.; Lynch, A.G.; Kingsbury, Z.; Ross, M.; Humphray, S.; Bentley, D.; Fitzgerald, R.C. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat. Genet., 2015, 47(9), 1038-1046.
[http://dx.doi.org/10.1038/ng.3357] [PMID: 26192915]
[55]
Timmer, M.R.; Sun, G.; Gorospe, E.C.; Leggett, C.L.; Lutzke, L.; Krishnadath, K.K.; Wang, K.K. Predictive biomarkers for Barrett’s esophagus: so near and yet so far. Dis. Esophagus, 2013, 26(6), 574-581.
[http://dx.doi.org/10.1111/dote.12015] [PMID: 23316980]
[56]
Konda, V.J.A.; Souza, R.F. Biomarkers of Barrett’s Esophagus: From the Laboratory to Clinical Practice. Dig. Dis. Sci., 2018, 63(8), 2070-2080.
[http://dx.doi.org/10.1007/s10620-018-5088-2] [PMID: 29713984]
[57]
Whiteman, D.C.; Appleyard, M.; Bahin, F.F.; Bobryshev, Y.V.; Bourke, M.J.; Brown, I.; Chung, A.; Clouston, A.; Dickins, E.; Emery, J.; Eslick, G.D.; Gordon, L.G.; Grimpen, F.; Hebbard, G.; Holliday, L.; Hourigan, L.F.; Kendall, B.J.; Lee, E.Y.; Levert-Mignon, A.; Lord, R.V.; Lord, S.J.; Maule, D.; Moss, A.; Norton, I.; Olver, I.; Pavey, D.; Raftopoulos, S.; Rajendra, S.; Schoeman, M.; Singh, R.; Sitas, F.; Smithers, B.M.; Taylor, A.C.; Thomas, M.L.; Thomson, I.; To, H.; von Dincklage, J.; Vuletich, C.; Watson, D.I.; Yusoff, I.F. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J. Gastroenterol. Hepatol., 2015, 30(5), 804-820.
[http://dx.doi.org/10.1111/jgh.12913] [PMID: 25612140]
[58]
Spechler, S.J.; Sharma, P.; Souza, R.F.; Inadomi, J.M.; Shaheen, N.J. American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology, 2011, 140(3), 1084-1091.
[http://dx.doi.org/10.1053/j.gastro.2011.01.031] [PMID: 21376940]
[59]
Harrison, R.; Perry, I.; Haddadin, W.; McDonald, S.; Bryan, R.; Abrams, K.; Sampliner, R.; Talley, N.J.; Moayyedi, P.; Jankowski, J.A. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol., 2007, 102(6), 1154-1161.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01230.x] [PMID: 17433019]
[60]
Reid, B.J.; Haggitt, R.C.; Rubin, C.E.; Roth, G.; Surawicz, C.M.; Van Belle, G.; Lewin, K.; Weinstein, W.M.; Antonioli, D.A.; Goldman, H. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum. Pathol., 1988, 19(2), 166-178.
[http://dx.doi.org/10.1016/S0046-8177(88)80344-7] [PMID: 3343032]
[61]
Montgomery, E.; Arnold, C.A.; Lam-Himlin, D.; Salimian, K.; Waters, K. Some observations on Barrett esophagus and associated dysplasia. Ann. Diagn. Pathol., 2018, 37, 75-82.
[http://dx.doi.org/10.1016/j.anndiagpath.2018.09.013] [PMID: 30312881]
[62]
Kedika, R.R.; Souza, R.F.; Spechler, S.J. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig. Dis. Sci., 2009, 54(11), 2312-2317.
[http://dx.doi.org/10.1007/s10620-009-0951-9] [PMID: 19714466]
[63]
Bennett, C.; Moayyedi, P.; Corley, D.A.; DeCaestecker, J.; Falck-Ytter, Y.; Falk, G.; Vakil, N.; Sanders, S.; Vieth, M.; Inadomi, J.; Aldulaimi, D.; Ho, K.Y.; Odze, R.; Meltzer, S.J.; Quigley, E.; Gittens, S.; Watson, P.; Zaninotto, G.; Iyer, P.G.; Alexandre, L.; Ang, Y.; Callaghan, J.; Harrison, R.; Singh, R.; Bhandari, P.; Bisschops, R.; Geramizadeh, B.; Kaye, P.; Krishnadath, S.; Fennerty, M.B.; Manner, H.; Nason, K.S.; Pech, O.; Konda, V.; Ragunath, K.; Rahman, I.; Romero, Y.; Sampliner, R.; Siersema, P.D.; Tack, J.; Tham, T.C.; Trudgill, N.; Weinberg, D.S.; Wang, J.; Wang, K.; Wong, J.Y.; Attwood, S.; Malfertheiner, P.; MacDonald, D.; Barr, H.; Ferguson, M.K.; Jankowski, J. BOB CAT Consortium. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am. J. Gastroenterol., 2015, 110(5), 662-682.
[http://dx.doi.org/10.1038/ajg.2015.55] [PMID: 25869390]
[64]
Evans, J.A.; Early, D.S.; Fukami, N.; Ben-Menachem, T.; Chandrasekhara, V.; Chathadi, K.V.; Decker, G.A.; Fanelli, R.D.; Fisher, D.A.; Foley, K.Q.; Hwang, J.H.; Jain, R.; Jue, T.L.; Khan, K.M.; Lightdale, J.; Malpas, P.M.; Maple, J.T.; Pasha, S.F.; Saltzman, J.R.; Sharaf, R.N.; Shergill, A.; Dominitz, J.A.; Cash, B.D. ASGE Standards of Practice Committee; Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest. Endosc., 2012, 76(6), 1087-1094.
[http://dx.doi.org/10.1016/j.gie.2012.08.004] [PMID: 23164510]
[65]
Krishnamoorthi, R.; Singh, S.; Ragunathan, K.; Visrodia, K.; Wang, K.K.; Katzka, D.A.; Iyer, P.G. Factors Associated With Progression of Barrett’s Esophagus: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol., 2018, 16(7), 1046-1055.e8.
[http://dx.doi.org/10.1016/j.cgh.2017.11.044] [PMID: 29199147]
[66]
Nguyen, T.; Duan, Z.; Naik, A.D.; Kramer, J.R.; El-Serag, H.B. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study. Gastroenterology, 2015, 149(6), 1392-1398.
[http://dx.doi.org/10.1053/j.gastro.2015.07.009] [PMID: 26208896]
[67]
Triadafilopoulos, G.; Friedland, S. Precision care for Barrett’s esophagus. Transl. Gastroenterol. Hepatol., 2018, 3, 67.
[http://dx.doi.org/10.21037/tgh.2018.09.10] [PMID: 30363757]
[68]
Das, D.; Chilton, A.P.; Jankowski, J.A. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res., 2009, 181, 161-169.
[http://dx.doi.org/10.1007/978-3-540-69297-3_15] [PMID: 19213566]
[69]
Nguyen, D.M.; Richardson, P.; El-Serag, H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology, 2010, 138(7), 2260-2266.
[http://dx.doi.org/10.1053/j.gastro.2010.02.045] [PMID: 20188100]
[70]
Richter, J.E.; Penagini, R.; Tenca, A.; Pohl, D.; Dvorak, K.; Goldman, A.; Savarino, E.; Zentilin, P.; Savarino, V.; Watson, J.T.; Wong, R.K.; Pace, F.; Casini, V.; Peura, D.A.; Herzig, S.J.; Kamiya, T.; Pelosini, I.; Scarpignato, C.; Armstrong, D.; DeVault, K.R.; Bechi, P.; Taddei, A.; Freschi, G.; Ringressi, M.N.; Degli’Innocenti, D.R.; Castiglione, F.; Masini, E.; Hunt, R.H. Barrett’s esophagus: proton pump inhibitors and chemoprevention II. Ann. N. Y. Acad. Sci., 2011, 1232, 114-139.
[http://dx.doi.org/10.1111/j.1749-6632.2011.06048.x] [PMID: 21950810]
[71]
Fitzgerald, R.C.; di Pietro, M.; Ragunath, K.; Ang, Y.; Kang, J.Y.; Watson, P.; Trudgill, N.; Patel, P.; Kaye, P.V.; Sanders, S.; O’Donovan, M.; Bird-Lieberman, E.; Bhandari, P.; Jankowski, J.A.; Attwood, S.; Parsons, S.L.; Loft, D.; Lagergren, J.; Moayyedi, P.; Lyratzopoulos, G.; de Caestecker, J. British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut, 2014, 63(1), 7-42.
[http://dx.doi.org/10.1136/gutjnl-2013-305372] [PMID: 24165758]
[72]
Gashi, Z.; Bahtiri, E.; Gashi, A.; Sherifi, F. Proton pump inhibitors diminish Barrett’s Esophagus length: Our experience. Open Access Maced. J. Med. Sci., 2018, 6(6), 1041-1045.
[http://dx.doi.org/10.3889/oamjms.2018.232] [PMID: 29983798]
[73]
Alsalahi, O.; Dobrian, A.D. Proton pump inhibitors: The culprit for Barrett’s Esophagus? Front. Oncol., 2015, 4, 373.
[http://dx.doi.org/10.3389/fonc.2014.00373] [PMID: 25621278]
[74]
Strand, D.S.; Kim, D.; Peura, D.A. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver, 2017, 11(1), 27-37.
[http://dx.doi.org/10.5009/gnl15502] [PMID: 27840364]
[75]
Shirasaka, Y.; Sager, J.E.; Lutz, J.D.; Davis, C.; Isoherranen, N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab. Dispos., 2013, 41(7), 1414-1424.
[http://dx.doi.org/10.1124/dmd.113.051722] [PMID: 23620487]
[76]
Sachs, G.; Shin, J.M.; Howden, C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment. Pharmacol. Ther., 2006, 23(Suppl. 2), 2-8.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02943.x] [PMID: 16700898]
[77]
Marelli, S.; Pace, F. Rabeprazole for the treatment of acid-related disorders. Expert Rev. Gastroenterol. Hepatol., 2012, 6(4), 423-435.
[http://dx.doi.org/10.1586/egh.12.18] [PMID: 22928894]
[78]
Fass, R.; Inadomi, J.; Han, C.; Mody, R.; O’Neil, J.; Perez, M.C. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin. Gastroenterol. Hepatol., 2012, 10(3), 247-253.
[http://dx.doi.org/10.1016/j.cgh.2011.11.021] [PMID: 22155561]
[79]
Röhss, K.; Hasselgren, G.; Hedenström, H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci., 2002, 47(5), 954-958.
[http://dx.doi.org/10.1023/A:1015009300955] [PMID: 12018920]
[80]
Shin, J.M.; Sachs, G. Long lasting inhibitors of the gastric H,K-ATPase. Expert Rev. Clin. Pharmacol., 2009, 2(5), 461-468.
[http://dx.doi.org/10.1586/ecp.09.33] [PMID: 21132072]
[81]
Inadomi, J.M.; Jamal, R.; Murata, G.H.; Hoffman, R.M.; Lavezo, L.A.; Vigil, J.M.; Swanson, K.M.; Sonnenberg, A. Step-down management of gastroesophageal reflux disease. Gastroenterology, 2001, 121(5), 1095-1100.
[http://dx.doi.org/10.1053/gast.2001.28649] [PMID: 11677201]
[82]
Mainie, I.; Tutuian, R.; Shay, S.; Vela, M.; Zhang, X.; Sifrim, D.; Castell, D.O. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut, 2006, 55(10), 1398-1402.
[http://dx.doi.org/10.1136/gut.2005.087668] [PMID: 16556669]
[83]
Meko, J.B.; Norton, J.A. Management of patients with Zollinger-Ellison syndrome. Annu. Rev. Med., 1995, 46, 395-411.
[http://dx.doi.org/10.1146/annurev.med.46.1.395] [PMID: 7598474]
[84]
Sjöstedt, S.; Befrits, R.; Sylvan, A.; Harthon, C.; Jörgensen, L.; Carling, L.; Modin, S.; Stubberöd, A.; Toth, E.; Lind, T. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment. Pharmacol. Ther., 2005, 22(3), 183-191.
[http://dx.doi.org/10.1111/j.1365-2036.2005.02553.x] [PMID: 16091055]
[85]
Chiba, T.; Malfertheiner, P.; Satoh, H. Proton Pump Inhibitors: A Balanced View., Frontiers of Gastrointestinal ResearchM; Frontiers of Gastrointestinal Research: Karger. , 2013.
[http://dx.doi.org/10.1159/isbn.978-3-318-02416-6]
[86]
Sachs, G.; Shin, J.M.; Vagin, O.; Lambrecht, N.; Yakubov, I.; Munson, K. The gastric H,K ATPase as a drug target: past, present, and future. J. Clin. Gastroenterol., 2007, 41(Suppl. 2), S226-S242.
[http://dx.doi.org/10.1097/MCG.0b013e31803233b7] [PMID: 17575528]
[87]
Dunbar, L.A.; Caplan, M.J. Ion pumps in polarized cells: sorting and regulation of the Na+, K+- and H+, K+-ATPases. J. Biol. Chem., 2001, 276(32), 29617-29620.
[http://dx.doi.org/10.1074/jbc.R100023200] [PMID: 11404365]
[88]
Poulsen, H.; Morth, P.; Egebjerg, J.; Nissen, P. Phosphorylation of the Na+,K+-ATPase and the H+,K+-ATPase. FEBS Lett., 2010, 584(12), 2589-2595.
[http://dx.doi.org/10.1016/j.febslet.2010.04.035] [PMID: 20412804]
[89]
Sakai, H.; Fujii, T.; Takeguchi, N. Proton-Potassium (H(+)/K(+)) ATPases: Properties and roles in health and diseases. Met. Ions Life Sci., 2016, 16, 459-483.
[http://dx.doi.org/10.1007/978-3-319-21756-7_13] [PMID: 26860309]
[90]
Shin, J.M.; Munson, K.; Vagin, O.; Sachs, G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch., 2009, 457(3), 609-622.
[http://dx.doi.org/10.1007/s00424-008-0495-4] [PMID: 18536934]
[91]
Shi, S.; Klotz, U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol., 2008, 64(10), 935-951.
[http://dx.doi.org/10.1007/s00228-008-0538-y] [PMID: 18679668]
[92]
Kim, J.S.; Park, J.H.; Jeong, S.C.; Kim, D.S.; Yousaf, A.M.; Din, F.U.; Kim, J.O.; Yong, C.S.; Youn, Y.S.; Oh, K.T.; Jin, S.G.; Choi, H.G. Novel revaprazan-loaded gelatin microsphere with enhanced drug solubility and oral bioavailability. J. Microencapsul., 2018, 35(5), 421-427.
[http://dx.doi.org/10.1080/02652048.2018.1515997] [PMID: 30136606]
[93]
Yu, K.S.; Bae, K.S.; Shon, J.H.; Cho, J.Y.; Yi, S.Y.; Chung, J.Y.; Lim, H.S.; Jang, I.J.; Shin, S.G.; Song, K.S.; Moon, B.S. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J. Clin. Pharmacol., 2004, 44(1), 73-82.
[http://dx.doi.org/10.1177/0091270003261321] [PMID: 14681344]
[94]
Inatomi, N.; Matsukawa, J.; Sakurai, Y.; Otake, K. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol. Ther., 2016, 168, 12-22.
[http://dx.doi.org/10.1016/j.pharmthera.2016.08.001] [PMID: 27514776]
[95]
Das, D.; Ishaq, S.; Harrison, R.; Kosuri, K.; Harper, E.; Decaestecker, J.; Sampliner, R.; Attwood, S.; Barr, H.; Watson, P.; Moayyedi, P.; Jankowski, J. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol., 2008, 103(5), 1079-1089.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01790.x] [PMID: 18445097]
[96]
Trifirò, G.; Corrao, S.; Alacqua, M.; Moretti, S.; Tari, M.; Caputi, A.P.; Arcoraci, V. UVEC Group. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br. J. Clin. Pharmacol., 2006, 62(5), 582-590.
[http://dx.doi.org/10.1111/j.1365-2125.2006.02687.x] [PMID: 16822281]
[97]
Krieg, L.; Milstein, O.; Krebs, P.; Xia, Y.; Beutler, B.; Du, X. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood, 2011, 118(24), 6418-6425.
[http://dx.doi.org/10.1182/blood-2011-04-350082] [PMID: 21976678]
[98]
Nehra, A.K.; Alexander, J.A.; Loftus, C.G.; Nehra, V. Proton pump inhibitors: Review of emerging concerns. Mayo Clin. Proc., 2018, 93(2), 240-246.
[http://dx.doi.org/10.1016/j.mayocp.2017.10.022] [PMID: 29406201]
[99]
Fawaz, M.V.; Brooks, A.F.; Rodnick, M.E.; Carpenter, G.M.; Shao, X.; Desmond, T.J.; Sherman, P.; Quesada, C.A.; Hockley, B.G.; Kilbourn, M.R.; Albin, R.L.; Frey, K.A.; Scott, P.J. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer’s disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS Chem. Neurosci., 2014, 5(8), 718-730.
[http://dx.doi.org/10.1021/cn500103u] [PMID: 24896980]
[100]
Gomm, W.; von Holt, K.; Thomé, F.; Broich, K.; Maier, W.; Fink, A.; Doblhammer, G.; Haenisch, B. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol., 2016, 73(4), 410-416.
[http://dx.doi.org/10.1001/jamaneurol.2015.4791] [PMID: 26882076]
[101]
Rojo, L.E.; Alzate-Morales, J.; Saavedra, I.N.; Davies, P.; Maccioni, R.B. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J. Alzheimers Dis., 2010, 19(2), 573-589.
[http://dx.doi.org/10.3233/JAD-2010-1262] [PMID: 20110603]
[102]
Carmona, M.A.; Murai, K.K.; Wang, L.; Roberts, A.J.; Pasquale, E.B. Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport. Proc. Natl. Acad. Sci. USA, 2009, 106(30), 12524-12529.
[http://dx.doi.org/10.1073/pnas.0903328106] [PMID: 19592509]
[103]
Ben Haim, L.; Carrillo-de Sauvage, M.A.; Ceyzériat, K.; Escartin, C. Elusive roles for reactive astrocytes in neurodegenerative diseases. Front. Cell. Neurosci., 2015, 9, 278.
[http://dx.doi.org/10.3389/fncel.2015.00278] [PMID: 26283915]
[104]
Jankowski, J.A.Z.; de Caestecker, J.; Love, S.B.; Reilly, G.; Watson, P.; Sanders, S.; Ang, Y.; Morris, D.; Bhandari, P.; Brooks, C.; Attwood, S.; Harrison, R.; Barr, H.; Moayyedi, P. AspECT Trial Team. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet, 2018, 392(10145), 400-408.
[http://dx.doi.org/10.1016/S0140-6736(18)31388-6] [PMID: 30057104]
[105]
Harrison, M.; Allen, J.E.; Gorrepati, V.S.; López-Jamar, J.M.E.; Sharma, P. Management of Barrett’s esophagus with low-grade dysplasia. Dis. Esophagus, 2018, 31(4)
[http://dx.doi.org/10.1093/dote/doy004] [PMID: 29506235]
[106]
Krajciova, J.; Vackova, Z.; Spicak, J.; Martinek, J. Radiofrequency ablation for Barrett’s esophagus-related neoplasia. Minerva Chir., 2018, 73(4), 366-377.
[PMID: 29806757]
[107]
Blevins, C.H.; Iyer, P.G. Endoscopic therapy for Barrett’s oesophagus. Best Pract. Res. Clin. Gastroenterol., 2015, 29(1), 167-177.
[http://dx.doi.org/10.1016/j.bpg.2014.11.007] [PMID: 25743464]
[108]
Pech, O.; Vieth, M.; Schmitz, D.; Gossner, L.; May, A.; Seitz, G.; Stolte, M.; Ell, C. Conclusions from the histological diagnosis of low-grade intraepithelial neoplasia in Barrett’s oesophagus. Scand. J. Gastroenterol., 2007, 42(6), 682-688.
[http://dx.doi.org/10.1080/00365520601075803] [PMID: 17505989]
[109]
Small, A.J.; Araujo, J.L.; Leggett, C.L.; Mendelson, A.H.; Agarwalla, A.; Abrams, J.A.; Lightdale, C.J.; Wang, T.C.; Iyer, P.G.; Wang, K.K.; Rustgi, A.K.; Ginsberg, G.G.; Forde, K.A.; Gimotty, P.A.; Lewis, J.D.; Falk, G.W.; Bewtra, M. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett’s Esophagus and confirmed Low-Grade dysplasia. Gastroenterology, 2015, 149(3), 567-76.e3.
[http://dx.doi.org/10.1053/j.gastro.2015.04.013] [PMID: 25917785]
[110]
Weusten, B.; Bisschops, R.; Coron, E.; Dinis-Ribeiro, M.; Dumonceau, J.M.; Esteban, J.M.; Hassan, C.; Pech, O.; Repici, A.; Bergman, J.; di Pietro, M. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy, 2017, 49(2), 191-198.
[http://dx.doi.org/10.1055/s-0042-122140] [PMID: 28122386]
[111]
Pouw, R.E.; Gondrie, J.J.; Rygiel, A.M.; Sondermeijer, C.M.; ten Kate, F.J.; Odze, R.D.; Vieth, M.; Krishnadath, K.K.; Bergman, J.J. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am. J. Gastroenterol., 2009, 104(6), 1366-1373.
[http://dx.doi.org/10.1038/ajg.2009.88] [PMID: 19491850]
[112]
Davila, M.L.; Hofstetter, W.L. Endoscopic management of Barrett’s esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma. Thorac. Surg. Clin., 2013, 23(4), 479-489.
[http://dx.doi.org/10.1016/j.thorsurg.2013.07.010] [PMID: 24199698]
[113]
Künzli, H.T.; Schölvinck, D.W.; Phoa, K.N.; Schoon, E.J.; Houben, M.H.; Bergman, J.J.; Weusten, B.L. Simplified protocol for focal radiofrequency ablation using the HALO90 device: short-term efficacy and safety in patients with dysplastic Barrett’s esophagus. Endoscopy, 2015, 47(7), 592-597.
[http://dx.doi.org/10.1055/s-0034-1391436] [PMID: 25675174]
[114]
Pouw, R.E.; Wirths, K.; Eisendrath, P.; Sondermeijer, C.M.; Ten Kate, F.J.; Fockens, P.; Devière, J.; Neuhaus, H.; Bergman, J.J. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early neoplasia. Clin. Gastroenterol. Hepatol., 2010, 8(1), 23-29.
[http://dx.doi.org/10.1016/j.cgh.2009.07.003] [PMID: 19602454]
[115]
van Vilsteren, F.G.; Phoa, K.N.; Alvarez Herrero, L.; Pouw, R.E.; Sondermeijer, C.M.; Visser, M.; Ten Kate, F.J.; van Berge Henegouwen, M.I.; Weusten, B.L.; Schoon, E.J.; Bergman, J.J. A simplified regimen for focal radiofrequency ablation of Barrett’s mucosa: a randomized multicenter trial comparing two ablation regimens. Gastrointest. Endosc., 2013, 78(1), 30-38.
[http://dx.doi.org/10.1016/j.gie.2013.02.002] [PMID: 23528655]
[116]
Pouw, R.E.; Künzli, H.T.; Bisschops, R.; Sondermeijer, C.M.; Koch, A.D.; Didden, P.; Gotink, A.W.; Schoon, E.J.; Curvers, W.L.; Bergman, J.J.G.H.M.; Weusten, B.L.A.M. Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett’s oesophagus: a multicentre randomised controlled trial. Lancet Gastroenterol. Hepatol., 2018, 3(8), 566-574.
[http://dx.doi.org/10.1016/S2468-1253(18)30157-2] [PMID: 29934224]
[117]
Phoa, K.N.; van Vilsteren, F.G.; Weusten, B.L.; Bisschops, R.; Schoon, E.J.; Ragunath, K.; Fullarton, G.; Di Pietro, M.; Ravi, N.; Visser, M.; Offerhaus, G.J.; Seldenrijk, C.A.; Meijer, S.L.; ten Kate, F.J.; Tijssen, J.G.; Bergman, J.J. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA, 2014, 311(12), 1209-1217.
[http://dx.doi.org/10.1001/jama.2014.2511] [PMID: 24668102]
[118]
Shaheen, N.J.; Sharma, P.; Overholt, B.F.; Wolfsen, H.C.; Sampliner, R.E.; Wang, K.K.; Galanko, J.A.; Bronner, M.P.; Goldblum, J.R.; Bennett, A.E.; Jobe, B.A.; Eisen, G.M.; Fennerty, M.B.; Hunter, J.G.; Fleischer, D.E.; Sharma, V.K.; Hawes, R.H.; Hoffman, B.J.; Rothstein, R.I.; Gordon, S.R.; Mashimo, H.; Chang, K.J.; Muthusamy, V.R.; Edmundowicz, S.A.; Spechler, S.J.; Siddiqui, A.A.; Souza, R.F.; Infantolino, A.; Falk, G.W.; Kimmey, M.B.; Madanick, R.D.; Chak, A.; Lightdale, C.J. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med., 2009, 360(22), 2277-2288.
[http://dx.doi.org/10.1056/NEJMoa0808145] [PMID: 19474425]
[119]
Bulsiewicz, W.J.; Kim, H.P.; Dellon, E.S.; Cotton, C.C.; Pasricha, S.; Madanick, R.D.; Spacek, M.B.; Bream, S.E.; Chen, X.; Orlando, R.C.; Shaheen, N.J. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett’s esophagus. Clin. Gastroenterol. Hepatol., 2013, 11(6), 636-642.
[http://dx.doi.org/10.1016/j.cgh.2012.10.028] [PMID: 23103824]
[120]
Kumar, S.; Iyer, P.G. Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness. Tech. Gastrointest. Endosc., 2018, 20(2), 75-81.
[http://dx.doi.org/10.1016/j.tgie.2018.02.002]
[121]
Pasricha, S.; Bulsiewicz, W.J.; Hathorn, K.E.; Komanduri, S.; Muthusamy, V.R.; Rothstein, R.I.; Wolfsen, H.C.; Lightdale, C.J.; Overholt, B.F.; Camara, D.S.; Dellon, E.S.; Lyday, W.D.; Ertan, A.; Chmielewski, G.W.; Shaheen, N.J. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin. Gastroenterol. Hepatol., 2014, 12(11), 1840-1847.
[http://dx.doi.org/10.1016/j.cgh.2014.04.034]
[122]
Tan, M.C.; Kanthasamy, K.A.; Yeh, A.G.; Kil, D.; Pompeii, L.; Yu, X.; El-Serag, H.B.; Thrift, A.P. Factors associated with recurrence of Barrett’s Esophagus after radiofrequency ablation. Clin. Gastroenterol. Hepatol., 2019, 17(1), 65-72.e5.
[http://dx.doi.org/10.1016/j.cgh.2018.05.042] [PMID: 29902646]
[123]
Timmer, M.R.; Brankley, S.M.; Gorospe, E.C.; Sun, G.; Lutzke, L.S.; Iyer, P.G.; Halling, K.C.; Krishnadath, K.K.; Wang, K.K. Prediction of response to endoscopic therapy of Barrett’s dysplasia by using genetic biomarkers. Gastrointest. Endosc., 2014, 80(6), 984-991.
[http://dx.doi.org/10.1016/j.gie.2014.06.023] [PMID: 25085335]
[124]
Gupta, N.; Mathur, S.C.; Dumot, J.A.; Singh, V.; Gaddam, S.; Wani, S.B.; Bansal, A.; Rastogi, A.; Goldblum, J.R.; Sharma, P. Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett’s esophagus? Gastrointest. Endosc., 2012, 75(1), 11-18.
[http://dx.doi.org/10.1016/j.gie.2011.06.040] [PMID: 21907985]
[125]
Dunbar, K.B.; Spechler, S.J. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review. Am. J. Gastroenterol., 2012, 107(6), 850-862.
[http://dx.doi.org/10.1038/ajg.2012.78] [PMID: 22488081]
[126]
van Sandick, J.W.; van Lanschot, J.J.; ten Kate, F.J.; Offerhaus, G.J.; Fockens, P.; Tytgat, G.N.; Obertop, H. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making. Cancer, 2000, 88(11), 2429-2437.
[http://dx.doi.org/10.1002/1097-0142(20000601)88:11<2429::AID-CNCR1>3.0.CO;2-H] [PMID: 10861416]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 11
Year: 2020
Published on: 17 July, 2020
Page: [975 - 987]
Pages: 13
DOI: 10.2174/1389557519666191015203636
Price: $65

Article Metrics

PDF: 19
HTML: 2